Advanced Filters
noise

cardiovascular-abnormalities Clinical Trials

A listing of cardiovascular-abnormalities medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 25 clinical trials
A Alban Baruteau

Characterization and Support for Neurodevelopmental Disorders Associated with Congenital Heart Defects

The leading cause of birth defects, Congenital Heart Defects (CHD) affect 12 million people worldwide and 41,000 newborns/year in Europe. It's a major cause of life-long morbidity and mortality, and a crucial public health issue. More than 50% of childs born with critical CHD will develop Neurodevelopmental Disorders (NDs), requiring …

3 - 11 years of age All Phase N/A

Creation of a French South-Eastern Database and DNA-bank of Congenital Heart Disease to Explore the Genetic Pathways

Congenital heart defects are seen in 0,8% of life births. In France this means more than 5000 newborns per year. The south-east region of France is particularly affected as a result of a higher birth rate and consanguinity, when compared to other regions. The majority of congenital heart diseases remain …

years of age All Phase N/A
M Mandy Pershing, MS

Improving Patient and Family Health Using Family-Centered Outcomes and Shared Decision-Making

This study is a randomized clinical trial where participants (parents of a fetus or neonate diagnosed with a life-threatening congenital heart disease (CHD)) will randomly be assigned to either receiving a web-based decision aid (DA) alone, or receiving the decision aid that includes a values clarification exercise. Because of the …

18 years of age All Phase N/A
A Allan R Kluser Sales, PhD

Inspiratory Muscle Strength Training in Post-Covid Syndrome

Patients with post-Covid-19 syndrome are at high risk of developing cardiovascular diseases 12 months after acute infection of COVID-19. We recently revealed that these patients have elevated muscular sympathetic nerve activity (MSNA), vascular dysfunction, impaired cardiac diastolic function, and reduced functional capacity. Considering that these outcomes are independent predictors of …

18 - 65 years of age All Phase N/A
L Laurence M Boon, MD, PhD

Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care

The phosphatidylinositol 3-kinase (PI3Kinase)/Protein Kinase B (AKT)/mammalian target of rapamycin (mTor) pathway plays a role on the development and the venous/lymphatic vascular organisations. The investigators want to study the efficacy and the safety of Rapamycin, an mTor inhibitor.

3 - 70 years of age All Phase 3
J Jian Ren, MD

An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations

This study is a single-arm exploratory trial conducted by Xuanwu Hospital, Capital Medical University, aiming to evaluate the efficacy and safety of everolimus monotherapy in adult patients with vascular malformations.

18 - 65 years of age All Phase 2
S Shokhida T Turdieva, M.D., D.Sc.

Development of Methods for Effective Treatment and Improvement of Common Somatic Diseases in Children

The goal of the clinical study is to clarify the course of common congenital, infectious, and non-infectious diseases in children living in Uzbekistan, and to develop methods for their treatment and rehabilitation. The main questions it aims to answer: Analysis of common congenital diseases among children; Analysis of commonly diagnosed …

3 - 15 years of age All Phase N/A
V Vincent MICHAUD, Dr

Functional Tests to Resolve Unsolved Rare Diseases. Rares.

Rares diseases are a heterogeneous group of conditions which need important tools for diagnosis. The use of high-throughput sequencing is able to diagnose half of the patients. For the other part it is impossible to conclude due to the presence of variants of unknown significance (VOUS). Functional analysis are needed …

years of age All Phase N/A

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, RLY-2608, in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose selection, Part 2 is a basket design with exploratory single-arm …

2 years of age All Phase 2
M Michelle de Silva, BSc(Hons), PhD, MGenCouns

A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations

Recent studies have demonstrated that growth of vascular malformations can be driven by genetic variants in one of 2 signalling pathways. Targeted drugs specific to these pathways have been developed and shown to be effective in treating cancer. This study will describe the effectiveness of (i) 48 weeks of alpelisib …

2 years of age All Phase 2

Simplify language using AI